Globavir Biosciences, Inc., a biotechnology company, announced a partnership with Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostics products.

Under the terms of the agreement, Bio-Rad will license Globavir's PanGlob dengue detection technology for use in an assay that includes dengue virus detection.  Financial terms of the agreement were not disclosed.

The PanGlob assay, originally developed by Stanford University researchers, includes improved diagnostic sensitivity, efficacy across all four dengue serotypes, and enhanced specificity for dengue over related viruses. This advanced technology reduces the risk of incorrect results.

"Infectious disease outbreaks are a threat to human health with the potential of quickly reaching an epidemic level," said Globavir CEO Dr Shalabh Gupta. "Correct diagnosis of these types of diseases is the crucial first step toward effective patient care and surveillance. Globavir is excited to lend our dengue technology toward the creation of this important assay."

"Bio-Rad is pleased to partner with Globavir for a dengue assay that provides improved sensitivity and specificity in detecting this virus," said Bio-Rad President Clinical Diagnostics Group John Hertia.

Globavir Biosciences is a biotechnology company developing life-saving technologies for treatment of oncology and infectious diseases.

Bio-Rad Laboratories, Inc.  develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets.